102 related articles for article (PubMed ID: 9293796)
1. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo.
Stein R; Goldenberg DM; Ong GL; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Sep; 38(9):1392-400. PubMed ID: 9293796
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels.
Patel S; Stein R; Ong GL; Goldenberg DM; Mattes MJ
J Nucl Med; 1999 Aug; 40(8):1392-401. PubMed ID: 10450693
[TBL] [Abstract][Full Text] [Related]
3. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
4. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
[TBL] [Abstract][Full Text] [Related]
5. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
[TBL] [Abstract][Full Text] [Related]
6. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
[TBL] [Abstract][Full Text] [Related]
7. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
8. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
9. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
10. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
Michel RB; Ochakovskaya R; Mattes MJ
Clin Cancer Res; 2002 Aug; 8(8):2632-9. PubMed ID: 12171895
[TBL] [Abstract][Full Text] [Related]
11. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
[TBL] [Abstract][Full Text] [Related]
12. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
13. Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography.
Demignot S; Pimm MV; Thorpe SR; Baldwin RW
Cancer Immunol Immunother; 1991; 33(6):359-66. PubMed ID: 1878889
[TBL] [Abstract][Full Text] [Related]
14. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
Shih L; Ong GL; Burton J; Mishina D; Goldenberg DM; Mattes MJ
Cancer Immunol Immunother; 2000 Jul; 49(4-5):208-16. PubMed ID: 10941903
[TBL] [Abstract][Full Text] [Related]
15. Single-cell cytotoxicity with radiolabeled antibodies.
Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
[TBL] [Abstract][Full Text] [Related]
16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
17. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
18. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.
Hornick JL; Sharifi J; Khawli LA; Hu P; Bai WG; Alauddin MM; Mizokami MM; Epstein AL
J Nucl Med; 2000 Feb; 41(2):355-62. PubMed ID: 10688122
[TBL] [Abstract][Full Text] [Related]
19. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
[TBL] [Abstract][Full Text] [Related]
20. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
